Today, students with parents, teachers and the state are returning to their classrooms to worry about the transmission of the coronavirus. It is noted that the Delta mutation has made him coronavirus highly contagious among students, while the platform for the vaccination of children over 12 years.
However, parents are reluctant to vaccinate their children against coronavirus, despite scientific assurances. It is reminded that students who have not been vaccinated are required to submit a negative self test twice a week. Read here in detail all the measures for the opening of schools.
At the same time, the Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens, Stavroula Paschou (Assistant Professor of Endocrinology), Theodora Psaltopoulou (Professor of Therapeutic-Preventive Medicine) and Thanos Aigatopas-Theopitos Theopoulos summarize the relevant data on vaccination of children.
The case of the FDA
The US FDA granted full approval last month for the use of the Pfizer vaccine in people over the age of 16. This was based on 6-month follow-up of clinical data. It was already approved for emergency use last December based on a shorter, 2-month follow-up.
In the same way, Pfizer and Moderna vaccines are currently approved for children over 12 years of age by the FDA (USA) and EMA (Europe). Both are mRNA vaccines, meaning they do not contain the virus or part of it but a set of information to train human cells to make a protein that will activate the immune system to produce protective antibodies.
Data for children 5 to 11 years old
A Pfizer spokesman said the data needed for children ages 5 to 11 is expected within the next month. Data for children aged 2 to 5 years will be available shortly thereafter. For children between 6 months and 2 years, Pfizer said it could have safety and efficacy data in November. Moderna also announced that it has completed the registration of participants in a clinical study for children between 6 and 11 years old, while conducting studies to select the most appropriate dose in even younger age groups.
U.S. regulators, for their part, have said that children in clinical trials for COVID-19 vaccines should be monitored for at least 2 months, suggesting that the fastest way to approve emergency use before full approval. The FDA also announced that every effort will be made to complete the data review as soon as possible, most likely in a few weeks and not months as usual.
Vaccines are our most important response to the pandemic. However, until the entire population is covered, including children, additional precautions, such as mask use, distances and possibly isolation in some cases, will be needed in the coming months.
The article Coronavirus – Vaccination of children: How safe it is – All the new data published in NewsIT .